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A B S T R A C T
We present an unusual case of primary intracranial carcinoid tumor of the skull base
centered at the level of the foramen jugulare, which was proven with surgical biopsy
and later with Somatostatin receptor nuclear medicine scan. We present the salient mag-
netic resonance imaging features of this rare tumor, describe their characteristic nuclear
medicine findings, and briefly review the literature.
Introduction
Carcinoid tumors are rare, slow-growing neuroendocrine neo-
plasms that most commonly arise in the gastrointestinal tract
(62-67%) or the bronchopulmonary airways (22-27%).1,2 In-
tracranial involvement by a carcinoid tumor is most commonly
seen due to hematogeneous metastasis. Primary intracranial
carcinoid tumors are rarely mentioned in the literature.3,4 We
report a case of a pathologically proven isolated carcinoid tu-
mor of the skull base. Extensive metastatic workup revealed no
other primary lesion, indicating this to be the primary site of
involvement.
Case Report
A 29-year-old female presented with progressive multiple cra-
nial nerve palsy including diplopia on rightward gaze, difficulty
with swallowing, and hoarseness of voice over the last 6 years.
She had complaints of headache, dizziness, and generalized
weakness. On examination she had decreased pinprick sensa-
tion on the right side of her face with decreased abduction of the
right eye, suggestive for right V and VI cranial nerve palsies,
respectively. There was decreased elevation of the right side of
her soft palate and right-sided deviation of the tongue on pro-
trusion, suggestive of CN IX and XII palsies, respectively. Her
sternocleidomastoid and trapezius muscles had full strength.
The patient denied any difficulty breathing, diarrhea, or flush-
ing. Twenty-four-hour urinalysis demonstrated no evidence of
elevation of 5-HIAA levels.
Magnetic resonance imaging (MRI) of the skull base demon-
strated a large mass lesion centered at the right foramen jugulare
extending superiorly into the cerebellomedullary angle cistern
(Figs 1A, B) and inferiorly into the right carotid and paraver-
tebral spaces of the upper neck (Fig 1C) and infiltration of the
ipsilateral cavernous sinus. Frank osseous invasion of the right
petrous temporal bone and right lateral aspect of the clivus
was noted. The lesion was predominantly isointense to the gray
matter on T1-weighted images (WI) and T2 WI. It showed
diffuse moderate homogeneous enhancement following con-
trast administration. Differential diagnosis based on imaging in-
cluded glomus jugulotympanicum, schwannoma, meningioma,
or metastasis.
Excisional biopsy of the lesion revealed a tan pink, well-
circumscribed soft tissue mass. The tissue had a firm, ho-
mogenous yellow-to-pink cut surface. Light microscopy showed
islands of monotonous cells with scant, pink granular cyto-
plasm, round-oval stippled nuclei with small nucleoli, and
minimal pleomorphism, with absence of necrosis and mitotic
activity (Fig 2A). Further immunohistochemical analysis with
neuroendocrine markers stained positive for chromogranin A
(Fig 2B) and synaptophysin (2B), and the lesion was diagnosed
as carcinoid tumor.
Following the biopsy result, the patient underwent a So-
matostatin receptor scintigraphy study using Indium 111 Pente-
treotide [111In-DTPA-D-Phe-] (Octreoscan), at 24 and 48 hours
(Fig 1D). It demonstrated avid radiotracer uptake in the right
upper neck and right skull base region, which corresponded
to the known lesion at the right skull base. No additional area
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Fig 1. MRI of the brain and skull base demonstrates carcinoid tumor centered at the right foramen jugulare extending superiorly into the
cerebellomedullary angle cistern (arrows). The lesion is predominantly isointense to the gray matter on T1-weighted images (WI) (not shown)
and T2 WI (A). It shows diffuse moderate homogeneous enhancement following contrast administration (B). There is inferior extension into the
right carotid space with forward displacement of the right internal carotid artery (arrowhead). There is extension into paravertebral spaces of
the upper neck (C) (black arrows) and into the ipsilateral cavernous sinus (not shown). (D) Planar anterior (left) and posterior (right) 48-hour
Octreotide images of the head, neck, and chest demonstrate avid radiotracer uptake in the upper right neck and right skull base region.
of abnormal uptake was noted. Extensive imaging of the chest,
abdomen, and pelvis showed no evidence of primary neoplasm
or additional metastasis. She was treated with monthly somato-
statin injections. She denied local radiation treatment. At 1-year
follow-up, her symptoms are stable and there was no interval
increase in the tumor size.
Discussion
Carcinoid tumors are relatively uncommon tumors arising from
Kulchitsky cells, an enterochromaffin cell located in the crypts
of Lieberkuhn of the intestinal lumen.1 They do not present
clinically until there has been metastatic spread or evidence of
carcinoid syndrome.1 Carcinoid syndrome is rarely manifested
in patients with central nervous system (CNS) lesions.3 De-
shaies and Huang reported CNS carcinoid mimicking a menin-
gioma,3,4 while other primary carcinoid tumors have been re-
ported in the orbit and middle ear.5,6 Very few (less than 2%)
patients with carcinoid tumors exhibit CNS metastasis, the com-
monest primary site being the lungs.7,8 Most patients with brain
metastasis have either primary lung tumors or metastasis to the
lung at the time of brain metastasis.7,8 Purely intraparenchymal
lesions are found in 58% of cases while 42% of the lesions have
meningeal involvement.6 Carcinoid metastasis to the brain oc-
curs after a variable time course with the median interval 16-18
months (range 0-16.3 years).8
Imaging of carcinoid tumor is often challenging, requiring
a combination of anatomic and functional techniques.9 Imag-
ing techniques include computed tomography (CT), MRI, so-
matostatin receptor (SR) scintigraphy, and, sometimes, positron
emission tomography. Imaging on MRI is nonspecific and with
findings similar to more common pathologies like glomus tu-
mor, meningioma, schwannoma, and metastasis. As most carci-
noid tumors express type 2 SRs, scintigraphy is widely used as
the primary imaging method for diagnosis, staging, and moni-
toring of carcinoid tumors.10 SR scintigraphy performed using
Indium111-labeled Octreotide is a sensitive method of localiz-
ing radiologically occult carcinoid tumors, with a reported sen-
sitivity of 80%-100%.11,12 Whole-body imaging technique may
provide valuable information about unsuspected metastatic dis-
ease especially when single photon emission CT (SPECT) data
are also obtained.
Primary intracranial carcinoid tumors are rare; conse-
quently, once a carcinoid tumor of the brain is suspected, it is
imperative to conduct a full body imaging using a combination
of anatomic and functional imaging to rule out any additional
lesions.
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Fig 2. Findings on histopathology. (A) Islands of monotonous cells
with scant, pink granular cytoplasm and round-oval stippled nuclei
(H&E, 400×). Chromogranin (B) and synaptophysin immunostain
show cytoplasmic positivity of the tumor cells, suggestive for car-
cinoid tumor.
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